Clinical trials under the direction of Melissa Gilliam, MD, MPH

The MINT Study # 15498A

Study Summary
An IUD is the most effective method of contraception. It is a small device that is easily placed in the uterus of the woman and prevents pregnancy. This study is being done to compare how female teenagers respond to two different FDA-approved IUDs.

Participation in this study will last approximately seven months. Subjects will be randomly assigned to receive one of two FDA-approved IUDs (Copper IUD or LNG-IUS). They will be given payment for their participation and asked to answer questions about their medical history, keep a diary to record their experience with the IUD, and make 4 visits to the study site: a screening visit, a visit to insert the IUD, and two follow-up visits in a private setting at the University of Chicago hospitals.

Participation Details:

  • Healthy, sexually active females age 14-18
  • Interested in long term, reversible contraception

To be eligible you must;

  • Have a regular menstrual cycles (21-35 days)
  • Not be currently pregnant and not planning a pregnancy within 6 months.

 

Study comparing the NuvaRing ® versus Ortho Tri-CyclenLo in College Women: (The ACCEPT Study) IRB # 14067B

Study Summary
The study is designed for women attending college or university who will be assigned to either the vaginal ring or the pill.

Subjects will undergo a pelvic exam and will be provided with a 3 months supply of either the vaginal ring or the pill. They will be asked to complete an online survey daily for three months, an online follow-up surveys at three months, and at six months.

Participation Details

  • Women aged 18 and above, currently in college or a graduate program
  • Interested in trying the contraceptive vaginal ring NuvaRing® or the oral contraceptive Ortho Tri-CyclenLo (a.k.a. The Pill)

To be eligible you must;

  • Not have used the contraceptive patch or oral contraceptives within the last month
  • Never have used a contraceptive vaginal ring

Study Director: Melissa Gilliam, M.D., MPH
Department: Obstetrics & Gynecology
Section of Family Planning
Patients eligible for the study should call the Research Line at: 773-834-7727
OR
Providers can call the Study Coordinator directly:
Rachael Pius 773-834-3284
rpius@babies.bsd.uchicago.edu

IUD After Cesarean Delivery Study

Study Summary

This research study will compare the use of a type of intrauterine device (IUD), the levonorgestrel-releasing intrauterine system (Mirena® IUD or LNG-IUS) inserted immediately after delivery of the placenta during your cesarean delivery versus the use of the Mirena® IUD placed 4-8 weeks following your cesarean section. The study will also examine differences in overall satisfaction with the method, expulsion (when the IUD comes out of the uterus on its own), menstrual periods and bleeding, other side effects and complications, pregnancy, and quality of life.

Once enrolled, women will be randomly assigned to either the group that receives the Mirena® IUD immediately after their cesarean delivery or the group that receives it 4-8 weeks following their cesarean delivery. Women will come in to the clinic for an enrollment visit and additional visits at 4-8 weeks, 3, 6 and 12 months after delivery. The study involves gynecologic and pelvic exams, pregnancy testing, completion of questionnaires and provision of personal and medical information. The questionnaires may ask some sensitive questions. All visits will take place at a private setting at the University of Chicago hospitals. Participants will receive $120 for participation in the study. The information gathered from this study may help improve IUD use among women after cesarean delivery.

Participation Details

• Women greater than or equal to 18 years old

To be eligible you must be:

• Pregnant now
• Planning to undergo a scheduled cesarean delivery.
• Desire to use the Mirena® IUD for contraception.

Study Director/Principal Investigator: Melissa Gilliam
Co-Investigator: Amy Whitaker
Department: Obstetrics & Gynecology
Section: Family Planning

For more information, contact:
Rachael Pius
5841 S. Maryland Ave., MC 2050
Chicago, IL 60637
(773) 834-7727
rpius@babies.bsd.uchicago.edu

A Phase III Trial Examining the Safety and Efficacy of an Experimental 12-Month Contraceptive Vaginal Ring (the Pop Council Study)

Study Summary
The research study will examine the safety and efficacy of an experimental contraceptive vaginal ring designed to last for 12 months and contains lower dosage of hormones than the birth control pill. Women enrolled in the study will participate in seven study visits over the course of one year and up to three telephone follow-up contacts over a period of 6 months, if needed. As part of the study, women will receive physical and gynecological exams and complete daily diaries. All visits will take place at a private setting at the University of Chicago. Participants will receive $250 for participation in the seven study visits. The study may result in a new birth control alternative for women.
Participation Details
• Women between 18 and 39 years old
• Interested in trying a new contraceptive vaginal ring
To be eligible you must be:
• In good general health
• Currently sexually active
• Willing to discontinue your current contraceptive method

Study Director/Principal Investigator: Antonia Nicosia, M.D
Department: Obstetrics & Gynecology
Section: Family Planning
For more information, contact:
Rachael Pius
5841 S. Maryland Ave., MC 2050
Chicago, IL 60637
(773) 834-7727
rpius@babies.bsd.uchicago.edu